serellan is an american video game developer founded in 2011 by christian allen .

the company has released one video game currently , takedown : red sabre for microsoft windows and xbox live arcade .

their second title , epsilon , is currently on steam early access .

serellan

go bankrupt serellan , i can ' t wait . not another single buck .
serellan llc is a video game development studio founded by games designer christian allen .
ks $ $ went to serellan . steam td sales $ $ went to 505 .
never have been so excited about a game for a long time ! great job serellan… .
allen has started a new company called serellan , and formed a small , experienced team .
the serellan studio consists of a selection of talented veterans with decades of experience developing video games .
it came down to the wire , but serellan hits its kickstarter funding goal for its tactical shooter takedown .
serellan llc is an indie game development team based in seattle , washington , founded in 2011 by christian allen .
it is not out of the realm of possibility that serellan never saw a dime from the sales of takedown .
fresh from steam early access , serellan studio’s epsilon brings some modern squad - based shooter tactics to pc . more »
fresh from steam early access , serellan studio ' s epsilon brings some modern squad - based shooter tactics to pc .
true . that ' s quite a bit of a downer . hopefully serellan sees to at least some compensation ( like the mentioned discounts ) .
@ serellan would you mind heading to @ epsilonthegame community hub to let people know how things are ? i don ' t seem to have the same effect .
game designer - unreal engine evangelist for north america at epic games - marine - ghost recon , halo : reach , lotr , serellan llc . bafta . tweets are mine alone .
after 23 years of service , there are many vessels that have been assigned to support starbase 118 ops that are recorded below . for ships that have been or are currently assigned to the area near the station , see the trinity - serellan defense fleet .
serellan and front - man christian allen can now start work on the game , planned for pc , ps3 and xbox 360 . the team includes developers from such games as ghost recon , halo : reach , rainbow six and f . e . a . r .
the kickstarted shooter from washington - based indie serellan was originally due to hit both windows pc and xbox 360 last year , but the developer had to delay the console version because it didn ' t pass certification requirements . that was fixed , but serellan chose to hold the xbla game back to add in post - launch improvements made to the pc version . the newly released xbla version also features the free dlc that was added post - launch , and that includes a range of new maps as well as some additional weaponry to mow one another down with .
anyway , from my understanding the way a lot of publishers do things in cases like this is provide the funds to have the game created ( along with handling marketing and distribution ) in exchange for ownership of the ip and a fraction of the income after the funds they provided have been repaid . so if 505 provided $ 2 million to have the game finished and the game only brought in $ 1 million in sales then serellan would not have seen a dime . however , if the game brought in $ 5 million gross then serellan would have gotten the previously agreed percentage from the $ 3 million net .
titles that make their way to steam early access vary in size by sometimes insanely wide margins , but occasionally you get something interesting with a storied pedigree behind it . such is the case with indie game studio serellan , which is staffed by veterans of the video game industry who have collectively worked on titles ranging from the
just to be clear : kickstarter backers sent money to serellan . steam purchasers sent money to 505 games ( and steam , and unreal ) . serellan saw exactly zero revenue from steam sales . yet we continued to update td on our own dime , for months , until we ran out of money and had to lay people off . i am not trying to argue with you , just clarify the situation . we have access to ks data , not steam data on sales ( since we did not publish td , we developed it for 505 , who published it . we cannot even access the financials page , we have request data from 505 ) .
launched in 2379 under jessa anassasi it was the first production vessel of the new wolverine . it was reassigned to starbase 118 later in 2379 where it acted as the base ' s support vessel for some time . the uss phoenix - c underwent refitting that was completed in 2384 , and at one point was part of the trinity - serellan defense fleet .
talk about cutting it close . after languishing well below its $ 200 , 000 kickstarter goal for almost a month for its proposed tactical shooter takedown , developer serellan finally made its number with less than three hours to go . the devs can credit a more in - depth kickstarter page and a last ditch promotion effort with only a week to go in the campaign .
constructed before the second borg incursion , the first voyage of the uss arrow was in the middle of that battle . she saw extensive combat during the dominion war , a conflict still evident on her battle scarred surface . in early 2383 she was assigned as the support vessel for starbase 118 until the arrival of the columbia later that year . the uss arrow now serves as part of the trinity - serellan defense fleet .
the whole project was originally in doubt as funds for the game were slow to come in . but a change to the kickstarter page ( complete with better game description and a tongue - in - cheek interrogation video ) , as well as a tweet from minecraft dev markus
notch
persson , helped push it over the top . as with all kickstarter projects , had serellan not reached its goal , it would have received nothing .
as is the case with any early access title , the team is still hard at work on updates for epsilon , but the shooter came with a decent amount of content at launch . chief among the offerings are a handful of single - player story missions , a starting set of core weapons , and an elimination mode that serellan says puts a premium on nonlethal combat . future updates to epsilon will bring in more story mode chapters , weapons , game modes , and the addition of cooperative multiplayer .
christian allen is an experienced aaa game designer and creative director . prior to founding serellan llc , christian served as lead designer , creative director , and design director of several aaa game projects for ubisoft , red storm entertainment , microsoft , bungie , and warner bros . games . christian’s titles include the award - winning tom clancy’s ghost recon advanced warfighter and halo : reach . titles he has contributed to have shipped over 15 million units , and earned over 20 “game of the year” awards in various categories .
christian allen and serellan will reward kickstarter funders in different ways . there are three tiers of involvement : silver , gold and platinum . pledging $ 50 or more gets you into the silver tier , where you ' ll be able to vote game content . pledging $ 100 or more gets you into the gold tier , allowing you to submit content for the game . and pledging $ 1000 or more gets you into the platinum tier , where you ' ll participate in
creative meetings , visit the studio , and much more
.
in order to complete the game they needed more than just the $ 221 , 834 they got from kickstarter ( minus the kickstarter fee of 5 % , leaving serellan with about $ 210k ) . this is where investors ( or , in this case , a publisher ) help make the game a reality . once a publisher gets involved things can get tricky , but it ' s entirely possible that 505 was serellans best option . no clue about other options , but it ' s possible that 505 was their only option , or even the only publisher willing to make a deal .
one of the most interesting aspects of epsilon is the aforementioned approach to nonlethal combat options . in modern military games it’s exceedingly rare to see much beyond the concept of racking up kill streaks and points for each lethal takedown , but serellan aims to reward players for choosing nonlethal measures . with any good reward , however , comes an equal or greater risk , because enemies who are taken down without lethal force may pop up later to pose a returning threat . with both lethal and nonlethal combat options , there’s a constant sub - game being played that puts an emphasis on fast reactions and on - the - fly decision making .
“epsilon emphasises both team play and tactics , with use of covert surveillance technology with interactive digital maps during a pre - mission planning phase and then squad based strategy during the mission itself . . where you need to bear in mind that while you may have laid out very careful plans , it can still go wrong ! ” n / a – may contain spoilers “there is a charm to seeing the bones of a game just being built , and certainly one as compelling as epsilon . ” n / a – gaming trend “overall this is a solid effort from serellan and with the tease of future features epsilon will be an indie title that you should keep an eye on . ” n / a – front toward gamer
you people should hide yourself . me and tons of other people spent money for that gigantic crap that is takedown and now you have the face to make another game . i don ' t care if you lost the rights or whatever , you should give everyone who throw money in the bin with that takedown crap at least a 50 % discount . but nooope , you said
sorry
and everything is fine . . . lol . if someone is happy this way , good for him . they probably bought this game their parent ' s money , but i didn ' t . a
sorry
and a video with a sad face doesn ' t fn fix anything . go bankrupt serellan , i can ' t wait . not another single buck .
what will the $ 200 , 000 be used for ? $ 200 , 000 will bring takedown to alpha . private investors are lined up , but unsure of the market for an old - school tac shooter . a successful kickstarter campaign will convince them that this is a viable market . along with their investment , pre - sales of the game ( a $ 15 kickstarter pledge is a significant discount on the final game price ) will also contribute to completion of the project . kickstarters will have access to a closed alpha . how can i help ? take a look at the reward levels and pledge what you feel comfortable with . then spread the word ! share this project on facebook , twitter , and other social media . tell news sites you want to find out more about it . share our website , urltoken . check out our twitter feed at @ serellan . thanks for taking the time to look over this project , feel free to send us any questions , or join our forums at urltoken / forums and get involved !
, priced $ 15 in north america and £12 / 15 euros across the ocean .
it ' s available now , along with watchos , tvos and homepod versions .
the company will launch an ipo on a ' recognized ' us stock exchange .
it comes with boards , fishing rods , a tent and a solar - powered shower .
the finally funding tally was $ 221 , 833 , and included some large last - minute donations , including one for the maximum $ 7 , 500 pledge . the difference between this kickstarter campaign and previous successful ones is that these funds will only take the game to the alpha stage , with private funding being sought to take the game to completion .
the pc version will be first - person , and first in the development queue . the ps3 version will be third - person and the xbox 360 view will be determined by feedback from fans . the goal is to have the game ready for release in june 2013 .
john keefer is a curmudgeon that has been in journalism for 35 years , the last 16 in the video games industry . he loves real - time strategy games and prefers old - school total annihilation to starcraft . he also loves isometric rpgs , and has been addicted to world of warcraft for more than 10 years . he sucks at shooters and multiplayer and is purely a pc guy . and being a former member of shack , he also likes chatty . go figure .
yes , i know this . i made a distinction between this and other kickstarter projects in my post .
early r6 games worked well with both views
wut ? they didn ' t have 3rd person . 3rd person isn ' t necessary in a game like . . .
an indie game development team based in seattle , washington , founded in 2011 by christian allen .
first in , can’t wait to see the finished game . keep up all of your hard work !
ghost recon advanced warfighter and halo : reach lead designer christian allen has taken to kickstarter to fund his resurrection of old - school , hardcore tactical shooters .
he ' s after $ 200 , 000 , and he ' s got until 1st april to make it . so far he ' s had 151 backers who ' ve pledged a combined $ 7448 .
for years , fans of tactical shooters have been crying out for someone to make a quality , hardcore , close - quarters combat tactical shooter ,
wrote allen on his kickstarter page .
but in contrast to these requests , game publishers eschew realism and tactics in exchange for ease of use and ' cinematic ' flavour .
[ tactical shooter fans ] don ' t care about a blockbuster cinematic experience ; they can already get that from cod or uncharted . they want a focused , challenging experience that leaves them satisfied in conquering it .
this campaign aims to see if my theory that real tactical shooters aren ' t dead , and that enough people want one to justify the cost of development .
we are focusing our initial development on a hardcore cqb tactical shooter ,
he shared .
this game will get back to the core of what is loved about the tac - shooter , featuring realistic weapon modelling , outfitting and commanding your squad , objective - based , non - linear missions set in real - world locations around the world , single player , co - op , and multiplayer .
the funding will help allen prove to investors that the appetite for such a game exists .
my approach is to look to the fans and what they have been asking about for so many years ,
allen explained in a separate interview with hookshot inc .
they don ' t care about a blockbuster cinematic experience ; they can already get that from cod or uncharted . they want a focused , challenging experience that leaves them satisfied in conquering it .
pitching that to a publisher , though , is like pitching a new flight sim . they think the genre is dead , like point and click adventure games supposedly are - double fine showed them the error of their ways .
this game will get back to the core of what is loved about the tac - shooter , featuring realistic weapon modelling , outfitting and commanding your squad , objective - based , non - linear missions set in real - world locations around the world , single player , co - op , and multiplayer .
tim schafer ' s double fine studio received overwhelming kickstarter support for an old school point and click adventure project . double fine sought $ 400 , 000 , but has received - with eight days to go - a staggering $ 2 . 4 million from 69 , 507 backers .
the rewards continue to scale up to donations of $ 10 , 000 or more , and they all stack , meaning that at $ 10 , 000 you receive every tier of rewards .
pledging top whack - $ 10 , 000 or more - gets you a custom baretta gun by christian allen himself . you can opt for a bbgun replica if the laws of your country / state don ' t allow this . $ 7500 or more has christian allen fly to your home town to organise a lan party ; $ 5000 or more involves a trip to the studio and to a shooting range ; and $ 2500 has your face and name put on a team member in the game .
sometimes we include links to online retail stores . if you click on one and make a purchase we may receive a small commission . for more information , go here .
bertie is senior staff writer and eurogamer ' s poland - and - dragons correspondent . he ' s part of the furniture here , a friendly chair , and reports on all kinds of things , the stranger the better .
the 10 most popular stories of the day , delivered at 5pm uk time . never miss a thing .
this site © 2018 gamer network . all rights reserved . no part of this site or its content may be reproduced without the permission of the copyright holder .
dear friends , as you know , i have been working for years to bring the concept of a tactical cqb . . .
update 1 . 07 is live ! in addition to new features and equipment , there are tons of fixes and improvements . . . .
join the game designer of graw and halo reach to help create the spiritual successor to the original rainbow six and swat4 .
in recent years , shooters have become homogenized . there used to be a wide range of different games to choose , from run - and - gun action titles to slow - paced tactical shooters focusing on strategy and tactics , but now most shooters follow the same model of big set pieces , regenerating health , linear levels , and “cinematic experiences . ” the realistic tactical shooters with in - depth planning have almost entirely disappeared in recent years .
this project , working title takedown , aims to change that . this game , the spiritual successor to games like the original rainbow six and swat series , will focus on realistic weapons modeling , squad based play , in a close - quarters battle setting . to succeed in this game you need to take things slow , study your plans , and execute flawlessly . if you get shot , there are consequences . you won’t be hiding behind a wall waiting for your health to regenerate . if a team member goes down , you will have to assess the situation and reallocate team members if necessary to complete the mission . don ' t expect all of the tools and plans to be forced fed to you - it is up to the player to ensure their team is equipped and ready for the tasks at hand .
takedown is a thinking - person’s shooter . the player that takes things slow , aims carefully , and plans their moves right will overcome the player who runs in with guns blazing . close - quarters battle brings the fight inside , as you would see swat teams or sof units taking down small numbers of dangerous adversaries . non - linear environments allow for multiple routes and tactics and add replayability . the operation to clear pirates from a hijacked oil tanker by russian special forces in may of 2010 is a perfect example of the types of missions in takedown .
you will plan your insertions and routes before going into the scenario , outfitting your teammates with weapons and equipment of your choosing , and then execute the mission . if one of your team members is killed , they are gone , and you have lost their valuable experience , so you have to be careful ! gameplay modes include single player , co - op , and competitive multiplayer . if you are a fan of old school shooters where thinking meant more than running and gunning or perks , or if you are just looking for something different in your shooter games experience , this is the project for you .
community involvement is crucial to the development of this title . based on the pledge level , community members will influence different features and content in the game , as well as being able to submit content for inclusion in the game . while this won ' t be a
design by committee ,
and the development team will make the final decisions , when it is appropriate to open it up to the community for things like available weapons , community members will have opportunities to vote and discuss with dev team members before the final decisions are made .
the finished full game , via digital distribution when it ' s released . also access to the private discussion forums and access to developer blogs .
the finished full game , via digital distribution when it ' s released . access to the private discussion forums and access to developer blogs .
a unit patch for the game ' s military unit , suitable for wear on your tactical vest . you know you have a tactical vest , for when the zombies come .
access to the silver community level , where you will be able to vote on weapons , locations , and features to be included in the game . includes all previous rewards .
your name in a special
kickstarter supporters
section of the credits . includes all previous rewards .
a pc cd copy of the game , drm free , along with a t - shirt with the game logo on it . all previous rewards included .
access to the gold community level , where you will be able to submit game content to be included in the final game if approved , along with credit for the content .
a collectors edition boxed set of the pc cd version of the game , including a set of dog tags with the unit logo on them , and an art book from the game . includes all previous rewards .
a military unit challenge coin with the insignia of the team on it . includes all previous rewards .
a dvd of the soundtrack of the game including all music tracks , signed by the composer . includes all previous rewards .
original poster of the cover of the game ( shipping is free in the u . s . , $ 10 shipping internationally ) . special thanks in the credits . includes all previous rewards .
get an in - game badge on your player model showing that you supported the project ! includes all previous rewards .
access to the platinum level community , where you will be able to participate in conference calls with dev team members to express your ideas . includes all previous rewards .
get your face in the game , on one of the team members , and have them named after you . includes all previous rewards .
tour the dev studio and go on a shooting trip with dev team members for an afternoon , shooting a range of different guns , including full - auto fun ( must be able to travel to seattle , wa ) ! includes all previous rewards .
christian allen , the creative director of the game , will fly to your hometown to host a lan party for you and your friends . lower 48 states only . includes all previous rewards .
© valve corporation . all rights reserved . all trademarks are property of their respective owners in the us and other countries .
that ' s a bit harsh ! i was very disappointed with tdrs after buying it day one . and even after the updates it left a lot to be desired . the price point for early access on this is so low that i ' m considering taking a punt on it even after my tdrs experience in the hope that it will be a lot better . just hoping it has controller support or if not planned in the future as i much prefer to game that way .
yes , the others got a giant banana where the sun doesn ' t shine , tho .
me and tons of other people spent money for that gigantic crap that is takedown and now you have the face to make another game . i don ' t care if you lost the rights or whatever , you should give everyone who throw money in the bin with that takedown crap
but nooope , you said
sorry
and everything is fine . . . lol . if someone is happy this way , good for him . they probably bought this game their parent ' s money , but i didn ' t .
a
sorry
and a video with a sad face doesn ' t fn fix anything .
you think this game is bad ? no it isnt . if you are to poor to pay 7 . 99 , go get a job
i payed 57nok to get into the ea , thats a medium priced frozen pizza in norway . or two 1 . 5 liters of coke . or about 30 minutes of parking in oslo .
i ' m still blown away at how few people understand the publisher / developer business concept . when you are developing a game for a publisher they call the shots . they will release it whenever they want in whatever state they feel . takedown was a very solid core game that was finacially dropped by the publisher in an alpha state . the people who screwed us over also screwed over the developers .
we discussed offering a discount to td purchasers , but steam does not allow you to offer a discount for owners of games from other publishers . for example , us and takedown or something like assassins creed .
there had to be a way to offer people a key or coupon after it ' s been verified they own takedown in steam . not saying $ 7 . 99 is a huge deal . . . but if owners of takedown got if for say $ 4 . 99 . . . it might have been an easier pill for them to swallow .
i agree that something should have been done . . . but i wont harp about it . that said . . . i don ' t think they need to
hide their face
. that ' s ridiculous . war z devs . . . they need to hide themselves away , change their names , get new ip ' s , etc . anything so people wont know it ' s them .
also , i ' m a customer too , i don ' t understand why
early backers
get the game for free and the others don ' t .
offer it from your website . make a way for your website to check if a certain steam account has the game and then bind the game copy to it , like fdev did . solved . . .
it ' s not even a lot to ask , since lots of people got the game for free , but every customer got fd up with takedown .
first off if you don ' t want to buy it for $ 7 . 99 then don ' t but stop whining about getting it free . i know as a owner of tdrs i receieved 4 extra copies for my troubles . i paid 14 . 99 for 5 copies basically 2 . 99 each . i have 30 + hours tracked in steam on the game and countless that didn ' t get tracked . let ' s just us the 30 number . i spent . 099 + cents for the game . yes less than 10 f - ing cents per hour to play it . that is less than a damn happy meal @ mickey d ' s . and we had fun playing it . holy sh * t how can that be ? ! ? anyways . if you bought the game you received free copies of tdrs as well so stop whining . don ' t want to support it and take a chance @ $ 7 . 99 then don ' t . but stop acting like you spent serious money on the game because we know better .
working around
steam policies is a no - go . they will remove the game . just like they recently did with a few titles that were
working around
their policies . some back end workaround is specifically forbidden by steam . do you really think that we wouldn ' t just bite the bullet and say
sure , td buyers get 30 % of our $ 7 . 99 price point
to get he positive press like we did when we gave the td ks ' ers free copied ? but we are not allowed . if we could do that it might move an extra 100k units . that would be a win for us and make us net $ $ . we simply can ' t .
you made a deal with 505 games , allowing them to publish your game , so it ' s your fault . and don ' t tell us you gain nothing from it , otherwise , there wouldn ' t be a deal in the first place .
steam data is available for everyone . it ' s 226 , 716 ± 12 , 093 copies of red sabre .
$ 200 , 000 will bring takedown to alpha . private investors are lined up , but unsure of the market for an old - school tac shooter . a successful kickstarter campaign will convince them that this is a viable market . along with their investment , pre - sales of the game ( a $ 15 kickstarter pledge is a significant discount on the final game price ) will also contribute to completion of the project . kickstarters will have access to a closed alpha .
without knowing any of the details of the publishing agreement they had this is all guess work , but this is exactly how a lot of publishers and labels work in many other industries . did you know most musicians have to pay for recording time in a studio for example ? labels provide the upfront cost but it ends up coming out of their paychecks . look up what courtney love said about making $ 1 million for a record to see what i ' m talking about .
hell , book publishers are the same way . authors are given an advance so they have some money before a book is finished , but that also gets paid back out of sales of the book ( sometimes with interest ) .
note : this is only to be used to report spam , advertising , and problematic ( harassment , fighting , or rude ) posts .
takedown is a thinking - person’s shooter ; brutal , hardcore and deadly - like the real thing . not for the faint hearted , takedown requires you to bring your ' a ' game - fps fans looking for an ultra hardcore experience only need apply !
- 43 % of the 16 user reviews in the last 30 days are positive .
- 38 % of the 3 , 326 user reviews for this game are positive .
sign in to see reasons why you may or may not like this based on your games , friends , and curators you follow .
the player that takes things slow , aims carefully , and plans their moves right will overcome the player who runs in with guns blazing . close - quarters battle brings the fight inside , as you would see swat teams or sof units taking down small numbers of dangerous adversaries . non - linear environments allow for multiple routes and tactics and add replayability .
this game focuses on realistic weapons modeling , squad based play , in a close - quarters battle setting . to succeed in this game you need to take things slow , study your environment , and execute flawlessly . if you get shot , there are consequences . you won’t be hiding behind a wall waiting for your health to regenerate . if a team member goes down , you will have to assess the situation and reallocate team members if necessary to complete the mission . don’t expect all of the tools and plans to be forced fed to you – it is up to the player to ensure their team is equipped and ready for the tasks at hand . with features such as realistic bullet penetration , accuracy , and recoil , choosing the proper weapons , ammunition , armor , and gear for the mission is up to you , so choose carefully .
gameplay modes include single player , co - op , and competitive multiplayer . if you are a fan of old school shooters where thinking meant more than running and gunning or perks , or if you are just looking for something different in your shooter games experience , this is the game for you .
fight smart in deadly , close quarters combat – players must think and move tactically , stay alert , watch , listen and choose wisely while setting up their squad for the perfect shot .
tackle engagements that are different every time – nonlinear maps allow for multiple tactics and approaches to both attack and defense . gamers must choose their gear to best execute strategy .
out think the enemy – gamers need to work closely and communicate well with their team to not only attack the enemy but to coordinate to secure multiple objectives .
to view reviews within a date range , please click and drag a selection on a graph above or click on a specific bar .
when enabled , will sort reviews by new helpfulness score . read more about it in the blog post .
you can use this widget - maker to generate a bit of html that can be embedded in your website to easily allow customers to purchase this game on steam .
there is more than one way to buy this game . please select a specific package to create a widget for :
© 2018 valve corporation . all rights reserved . all trademarks are property of their respective owners in the us and other countries .
vat included in all prices where applicable . privacy policy | legal | steam subscriber agreement | refunds
epsilon is a hybrid stealth - action near - future tactical shooter where pre - planning and commanding your squad is essential for survival . through high intensity kinetic operations , epsilon is the unit tasked by unipol to counter eastern european militias engaged in human trafficking .
get instant access and start playing ; get involved with this game as it develops .
this early access game is not complete and may or may not change further . if you are not excited to play this game in its current state , then you should wait to see if the game progresses further in development .
“joining epsilon early access is a chance to experience the game as it evolves throughout its development process . be aware that our early access offer is a representation of our core pillars , and the framework we have created around them . it is a work in progress and therefore contains a variety of bugs . we strongly advise you not to buy and play the game at this stage unless you clearly understand what early access means and are interested in participating in the ongoing development cycle .
by self - publishing on ea , we hope to keep our small team independent and not rely on a publisher . we have self - funded to this point , and hope to avoid the distraction of a crowdfunding campaign to focus on game development .
by joining us in early access , you will have a chance to see the game grow and change , with your feedback integral to that process .
percentages are based on current game state estimates , not indicative of content numbers .
“we want to ensure that our players have the best experience possible on launch , so we want to take our time during early access to incorporate player feedback , work out any bugs , and adjust and expand features . we anticipate a full release within a year or so . ”
“epsilon will continue to grow and evolve throughout development , and features will be refined and adjusted based on player feedback . players can look forward to exciting content , such as : co - op , multiplayer , multiple squads , increasing ability and orders available to squad ai , and an expanding library of maps , missions , weapons , gadgets , game modes and player abilities . ”
“currently in early access there are 2 fully playable maps , both setup in story & elimination modes , a core set of weapons and abilities , per - mission surveillance and planning , and mission scoring . ”
“yes . as we release new features and content , the price will increase . we feel that the current pricing relflects the amount of content currently available , and we will adjust the price accordingly as new content , features , and fixes come online . ”
“we believe that player feedback should play a major role in the development of our games and invite players to make use of our various channels to deliver that feedback . primary channels are on our steam forums , and our own game forums at urltoken
processor : quad - core intel or amd , 2 . 5 ghz or faster
sony santa monica makes us care about kratos in this stunning revival of the series .
far cry 5 ' s story is a real let - down , but the action still makes for a solid co - op experience .
there are some elements around the edges that haven ' t aged all that well , but burnout paradise is still a fantastic racing game .
podcasts giant bombcast the giant beastcast giant bombcast ( premium ) the giant beastcast ( premium ) giant bombcast aftermath ! all systems goku premium podcasts giant bomb presents gaming minute 8 - 4 play alt + f1 bombin ' the a . m . with scoops and the wolf !
bungie , microsoft , monolith , surreal , red storm , wargamer , ubisoft , snowblind and more .
the company is currently ( as of april 2012 ) working on takedown , a squad - based shooter for the pc , ps3 and xbox360 .
beware , you are proposing to add brand new pages to the wiki along with your edits . make sure this is what you intended . this will likely increase the time it takes for your changes to go live .
until you earn 1000 points all your submissions need to be vetted by other giant bomb users . this process takes no more than a few hours and we ' ll send you an email once approved .
because you ' re new to wiki editing , we sent your submission off to our moderators to check it over . most changes are approved within a few hours . we ' ll send an email when it is .
points you ' ll be able to bypass this step and make live edits to our system . until then , gain points by continuing to edit pages .
president franklin d . roosevelt took the bullet - proofed yacht the uss potomac on two of the greatest diplomatic missions of wwii .
the soviet air force’s ilyushin il - 2 “storm bird” took a heavy toll in german armor on the eastern front .
the author , a rifleman in “love” company , 399th infantry regiment , 100th infantry division , recalls brutal winter combat on the french - german border .
, a squad - based tactical shooter influenced by current events and available to dig into via early access .
we compare the decade’s top military games in this 60 - page free issue . get your copy of warfare history network ’s free special report , the decade’s best military games
the gadgets and weapons available in epsilon so far run the gamut , and most will be familiar to those well versed in squad - based shooting . stuff like cameras that can slide under doors for a sneaky peek at enemies , unmanned weapons that can be operated remotely , and other gadgets significantly expand tactical options . of course , it’s crucial to go into a mission knowing what you’ll need and how you plan on succeeding , and that’s where premission planning comes into play . players can use digital maps to coordinate their squad and note enemy positions , preparing in advance for any possibilities that may arise . if you end up halfway through a mission before realizing your plan isn’t going to work , you can always ditch it and switch things up accordingly .
epsilon ’s story touches on matters like the ongoing eastern european crisis , the current state of america , and more . dr . stacy cecchet , seattle university’s adjunct professor of criminal justice , has served as an adviser on the subject matter throughout the development process , so it should be interesting to see what future story missions come out of the collaboration . at the moment it’s a good time to give epsilon a spin , because while the kinks are still being worked out on a regular basis , those who try it out now can get in before the price rises incrementally leading up to the game’s full launch in early 2016 .
register now to gain access to all of our features . once registered and logged in , you will be able to contribute to this site by submitting your own content or replying to existing content . you ' ll be able to customize your profile , receive reputation points as a reward for submitting content , while also communicating with other members via your own private inbox , plus much more ! this message will be removed once you have signed in .
originally conceived by mustafa
moose
thamer at a three - day brainstorming retreat with clancy , rainbow six was designed explicitly to eschew the twitch - based gameplay of the era ' s quake clones . based on the real - life exploits of the fbi ' s hostage rescue team , this was to be a game where you could bleed out from a single bullet wound . reflexes would rarely play a role in victory . instead , success would come from careful operations , selection of ordnance , and the planning stage , a pre - battle strategizing session that let you lay out the positions and pathing of your computer - controlled operatives . it was too robust a design to stay merely in the realm of hostage rescue , and eventually grew to encompass a variety of counter - terrorist activities .
it wasn ' t easy getting there , though .
we were trying to make four games simultaneously and had completely underestimated the workload ,
upton explains .
as the schedule started slipping we went into permanent crunch . frank boosman , our head of production and one of the principal founders , was let go halfway through production . i pretty much expected the whole thing to implode at any moment .
however , at the same time , the excitement level on the team for rainbow six was steadily growing . i remember one great moment where we were testing multiplayer and two players walked into a room and started blasting away , completely missing each other . then one of them held still , waited for his targeting reticle to settle , and got a one - shot kill with a perfect headshot . that was when we knew we had a completely different shooter experience on our hands .
stuart white , currently the senior producer on ghost recon : future soldier , was a tech support representative at red storm at the time . he , too , remembers these last incredible moments when rainbow six came together .
i ' ve said it before , i ' ll say it again ,
he told us .
it was an experience unlike anything else .
the hard work and impossible hours paid off . the result was a brutally challenging yet remarkably playable
thinking man ' s shooter
that was leagues ahead of the other
realistic
military games of the ' 90s .
to this day i still haven ' t seen anything like it ,
white notes ,
as far as a combination of action and strategy . it allowed the player who was really into just action to have an experience that they wanted . or , if you wanted to be a strategy guy , you could actually sit there for like two hours and make these detailed plans with go codes .
with two disparate groups of players enamored , red storm was secure , and tom clancy ' s gaming legacy was born .
neat article . if we were an experienced dev team back then r6 never would have gotten made . it was that inexperience and drive to suceed that made it all work . we didn ' t know any better . the absolute best times of my life .
this
rumor
about selling to ubi to get on consoles wasn ' t correct . the reason we sold was because we had mere months of money in the bank due to spending it on projects that didn ' t sell . rse most likely would have gone under otherwise .
it was nice but they don ' t really acknowledge how the gameplay shift was bad . they even said that vegas was a much needed change to the series . i stopped reading there .
the sum of all fears actually sold ok and made some money . but that was due more to it ' s low dev budget than actual sales . plus we might have gotten a bit of kickback from paramount on it , not sure .
the non sellers were dominant species , force 21 , shadow watch and politika . those all had full size dev teams and budgets . one of the biggest money suck early on was putting the mini discs in the politika paperback books . that was expensive and wasted a lot of money for no gain . the article gives a hint about who ' s sole idea that was .
it ' s funny , but there are so many internal issues and forces that make companies do things that the general public has no idea about . there were other attempts to buy rse for much more , but the powers that be held out for more . . . . . with those ultimately losing interest . in the end it was go with ubi ( who got us at a complete steal ) or risk drying up and going away .
just remember - before vegas , everyone had to suffer through lockdown . by that point , it did need a change . as standalone games , i happen to like the rainbow six : vegas games very much . they ' re just not rogue spear .
just a point of reality . gr2 was not originally designed purely to be an xbox title . it was originally pc . then the focus was turned to xbox , and then pc was cancelled .
i was involved in quite a few of these titles , and ign didnt bother to ask me anything . not surprised . this is a pr piece .
# # # # # # it and # # # # # # ign .
i agree that vegas 1 / 2 were okay for what they were and lockdown was even worse , but the correct thing to do was to make a raven shield sequel .
the rainbow 6 patriots video at the top of the page seemed like a dead giveaway that they had the intention of advertising for ubisoft .
i left after all the gr pc mission packs were out and before gr2 got underway . then i came back and did some contracting with rse on some of the gr2 stuff ( simply an art monkey only ) so from gr2 on christian knows the ins and outs .
yeah , ign did all kinds of pr stuff for ubisoft right before future soldier . they also did this .
when gr2 came out i thought it was odd that they would target exclusively for consoles , as well as downgrade to a teen rating . even so , the teen rating arguably made the game harder - since there was no blood , you were never really sure if a tango was down for good .
just another reminder to be very sceptical about these so called big game sites . most of them live off the ads from the games they review and are afraid to be / or are honest / biased / fanboy in fear of not being invited to the next press event etc .


silence therapeutics ( aim : sln ) is a biotechnology company that develops gene therapeutic technology based on rna interference ( rnai ) .

they are involved in developmental research of targeted rnai therapeutics for the treatment of serious diseases .

formed in 1994 as a publicly traded drug research and development company , silence therapeutics has offices in london and berlin , with its corporate headquarters at 1 lyric square , london .

silence therapeutics

silence therapeutics strives to conduct its business in an ethical , responsible and transparent manner .
silence therapeutics plc’s iss governance qualityscore as of n / a is n / a .
silence therapeutics develops these structural modifications using three exclusive licences from the university of massachusetts .
arrowhead nets $ 9 . 6m investment from u . k . - based silence therapeutics
silence therapeutics daily update : silence ther . is listed in the pharmaceuticals & biotechnology sector of the london stock exchange with ticker
glassdoor gives you an inside look at what it ' s like to work at silence therapeutics , including salaries , reviews , office photos , and more . this is the silence therapeutics company profile . all content is posted anonymously by employees working at silence therapeutics .
silence therapeutics share price . sln - stock quote , charts , trade history , share chat , financials . silence ther . ord 5p
xconomy : arrowhead nets $ 9 . 6m investment from u . k . - based silence therapeutics
silence therapeutics website uses cookies . by continuing to browse you are agreeing to our use of cookies .
silence therapeutics is an aim listed biotechnology company focused on the discovery , delivery and development of novel rna therapeutics for the treatment of serious diseases with unmet medical need .
aim - quoted rna therapy specialist silence therapeutics plc ( lon : sln ) has bolstered its patent protections in the united states .
, chief scientific officer of silence , said :
these notifications from the uspto further strengthens silence ' s ip position in the arena of rnai therapeutics and builds upon the already strong proprietary technology silence offers its partners . the broad range of rnai therapeutics in terms of their possible length of base pairs again distinguishes silence from competitors which provide coverage for only very few lengths , if any .
silence therapeutics plc on thursday said it notes a press release from quark pharmaceuticals inc , reporting positive results from a phase 2 . . .
silence therapeutics is focused on the discovery , delivery and development of novel rna therapeutics for the treatment of serious diseases with unmet medical need . using its proprietary rna interference ( rnai ) technology and delivery systems , the company has a strategy of creating a new generation of therapeutics to help patients and grow shareholder value .
i applied through college or university . the process took 5 days . i interviewed at silence therapeutics ( berlin ( germany ) ) in january 2013 .
the targeting , delivery and on - going structural modification of sequences are the three platforms for silence therapeutics’s rnai therapeutic development . these three platforms are :
london , uk & nijmegen / utrecht , netherlands , september 12 , 2011 – silence therapeutics plc ( aim : sln ) ( “silence” ) , a leading global rna interference ( rnai ) therapeutics company , and interna technologies b . v . ( “interna” ) , a biopharmaceutical company developing pathway targeted microrna ( “mirna” ) - based therapeutics for cancer , today announce that they have entered into an agreement to develop novel microrna therapeutics for the treatment of cancer . this will combine the delivery capabilities of silence’s proprietary atuplex™ delivery system with interna’s novel micrornas .
silence therapeutics plc focuses on the discovery , development , and delivery of novel rna therapeutics . the company designs short interfering rna ( sirna ) molecules that trigger the rnai pathway and mediate the degradation of specific target messenger rnas . it is developing various candidates for the treatment of cancer , iron overload disorders , cardiovascular disease , alcohol use disorder , and other metabolic diseases . the company was formerly known as sr pharma plc and changed its name to silence therapeutics plc in may 2007 . silence therapeutics plc was incorporated in 1994 and is headquartered in london , the united kingdom .
silence therapeutics’ technology is protected by a valuable patent portfolio , which strengthens its competitive position within the industry and provides opportunities for licensing its technology to third - parties .
silence therapeutics has 781 number of twitter followers . the number of followers has grown 0 . 6 % month over month and grown 1 . 9 % quarter over quarter
silence therapeutics , a publicly traded biotech firm based in the u . k . , said it has made a $ 9 . 6 million equity investment in arrowhead pharmaceuticals .
rna therapeutics company silence therapeutics plc ( lse : sln ) named dmitry samarsky cso , effective sept . 14 . he was svp of technology and global business development at olix pharmaceuticals inc . ( seoul , south korea ) . vaccine company paxvax inc . ( redwood . . .
we have developed proprietary modifications to improve the robustness of rna sequences , together with advanced liposomal chemistries to enhance the delivery of therapeutics . this allows the development of therapeutics for diseases with high unmet clinical need . silence’s technology is currently in the clinic in a phase 2a pancreatic cancer trial .
the company ' s rnai therapeutic platform has received key validation through multiple partnerships with pharmaceutical companies including astrazeneca , dainippon sumitomo , pfizer / quark , and novartis / quark . silence is actively pursuing the establishment of additional partnerships . silence therapeutics has operations in both
silence therapeutics is a drug development company with a proprietary genetic medicine platform . silence operates in the maturing field or rna therapeutics , which harnesses the body’s natural mechanisms to create therapeutic effects within its cells . this technology can selectively silence or replenish the expression of any gene in the genome . we have developed proprietary modifications to improve the robustness of rna sequences , as well as advanced chemistries to enhance the effective delivery of therapeutic rna molecules to target cells .
forward - looking statements this press release includes forward - looking statements that are subject to risks , uncertainties and other factors . these risks and uncertainties could cause actual results to differ materially from those referred to in the forward - looking statements . all forward - looking statements are based on information currently available to silence therapeutics and silence therapeutics assumes no obligation to update any such forward - looking statements .
neuromuscular disease company sarepta therapeutics inc . ( nasdaq : srpt ) hired louise rodino - klapac as vp of gene therapy at its newly created gene therapy unit . she will continue to serve as acting cso at myonexus therapeutics inc . ( new . . .
the grant of us 9 , 695 , 423 is further confirmation by the us patent office of the validity of our patent claims that protect our innovative chemical modification technology , ” said ali mortazavi , silence therapeutics chief executive .
silence therapeutics’ rnai technology can selectively silence any gene in the genome , modulating gene expression down in a variety of organs and cell types , in vivo . the company has developed proprietary modifications to improve the robustness of rna sequences , as well as advanced chemistries to enhance the effective delivery of therapeutic rna molecules to target cells .
silence therapeutics plc ( aim : sln ) , a leading rna interference ( rnai ) therapeutics company , today announced that the us patent and trademark office ( uspto ) has issued a notice of allowance indicating that it will grant patents based on two applications : 12 / 986 , 389 and 13 / 230 , 084 . these cover respectively interfering rna molecules and lipid complexes used in drug delivery .
our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients and , in the process , build shareholder value .
– potential for corporate activity . in our view , silence therapeutics’ current valuation should put the company on the radar of a number of potential suitors , whether they be in the rnai field already or looking to enter the sector by buying a valuable portfolio of rnai technology .
under the terms of the agreement , interna will provide silence with specific mirna sequences , which silence will formulate with its atuplex™ delivery system in order to develop multiple candidate drugs . silence and interna will undertake in vitro and in vivo studies of the candidate drugs developed under the agreement and select lead candidates for further evaluation . silence is eligible to receive upfront fees as well as staged research payments . further financial terms of the deal were not disclosed .
silence’s technology is clinical stage and is currently in active phase 2 and phase 3 trials carried out by a licensee .
silence said it believes that the granted patent claims are relevant to third party medicines that are in ongoing clinical trials .
silence therapeutics wants to put the kibosh on disease - causing genes . the company works in the field of rna interference ( rnai ) , a cutting - edge approach to treating disease that involves interfering with , or silencing , targeted genes associated with disease . its atuplex drug . . .
silence is currently conducting a phase i trial with atu027 in patients with advanced solid cancer . atu027 is based on silence´ proprietary atuplex™ delivery technology . interim data analysis from this trial were presented at the 2011 american society of clinical oncology conference and showed that atu027 is safe and well tolerated and provided broad support for atuplex™ as an effective sirna delivery technology with the potential to overcome the delivery challenges currently associated with rnai therapeutics .
supporting its ip portfolio , silence therapeutics has its own internally developed drug development programmes , along with a number of out - licenced programmes which use its technology . the company’s headline strategy is the development of its programmes , with highly stringent go / no - go criteria applied prior to making investment decisions .
the new us patent , ref 9 , 695 , 423 , provides further protection for silence ' s innovative chemical modification technology .
silence ther . has a 4 week average price of 134 . 50p and a 12 week average price of 130 . 50p .
the all - cash transaction could be a forerunner to discussions over a licensing deal or r & d collaboration , silence said . “we look forward to opening a constructive dialogue with arrowhead , ” ali mortazavi , silence’s ceo , said in a prepared statement .
interference ( rnai ) therapeutics for the treatment of serious diseases . rnai is a natural cellular process that occurs in almost all organisms and results in the silencing or shutting down of a target gene protein product . in an effort to combat a wide range of diseases , therapeutics that exploit the rnai process are being developed to halt the production of disease - causing proteins .
dr roel schaapveld , chief executive officer of interna technologies , said : “we are very excited about this collaboration with silence . working with atuplex™ and the experienced team at silence fits perfectly in our strategy to address the delivery challenge of rna based therapeutics upon systemic administration . atuplex™ may significantly contribute to the efficacy of several mirna drug candidates in our pipeline that have shown to reduce tumor growth in vivo and as such supports further development of these drug candidates towards the clinic . ”
the company has a history going back to january 1999 when atugen ag , a german biotechnology company focused on developing rnai therapeutics , was spun out of nasdaq listed ribozyme pharmaceuticals . in july 2005 atugen then completed the reverse takeover of aim listed sr pharma in conjunction with a £10 million fundraising and the business changed its name to silence therapeutics in may 2007 in order to reflect its increasing focus on rnai technology . the most recent capital raise was completed in may 2015 , with a gross £40 million being raised via a fundraising at 240p per share .
our technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells . this technology can selectively silence or replace any . . .
in april 2005 silence signed an option and licence agreement with quark pharmaceuticals giving quark access to the company’s aturnai® technology . there are currently four key programmes undergoing clinical trials which could create value for silence under the deal , in the near to medium - term , by generating milestone and royalty payments .
silence therapeutics plc ( lse : sln ) , london , u . k . business : cancer , pulmonary date announced : 2015 - 04 - 08 type : placing to be raised : up to l40 million ( $ 59 . 7 million ) shares : 16 . 7 million price : 240p shares outstanding prior : 52 . 1 million investor : institutional . . .
silence committed a sizable chunk of its cash reserves with the deal . the company said it had about $ 58 million in cash as of last june .
silence therapeutics plc ( lse : sln ) , london , u . k . business : cancer , renal , ophthalmic date announced : 2015 - 04 - 02 type : placing to be raised : up to l27 . 3 million ( $ 40 . 5 million ) shares : 11 . 4 million price : 240p shares outstanding prior : 52 . 1 million investor : . . .
thomas christély , chief operating officer of silence therapeutics , said : “we are pleased to be collaborating with interna , and it is in our interest to broaden the potential value of our atuplex™ delivery system as a vehicle to modify gene expression using different oligonucleotide classes , alongside our continuing focus on our internal sirna therapies . functional delivery into target cells is one of the greatest challenges facing most nucleic acid therapies . silence remains committed to the development of its atuplex™ and other delivery systems including dacc and dbtc as it seeks to overcome these challenges . ”
“as previously stated , we will consider potential licences under our patent estate , which could have a significant financial effect relative to the current market capitalisation of silence .
we will consider potential licences under our patent estate , which could have a significant financial effect relative to the current market capitalisation of silence .
says ceo ali mortazavi
silence had been evaluating several different rnai - focused companies and technologies since raising the equivalent of about $ 48 million from investors in 2015 , according to a news release .
silence therapeutics’ stake building comes in the midst of a difficult time for arrowhead in terms of its perception amongst investors and operational performance , the shares having fallen from just over 800 cents in august last year to their current levels of sub - 200 cents . this was primarily a result of arrowhead making the decision at the end of november to discontinue all three of its clinical programmes which utilised the firm’s proprietary delivery vehicle ex1 .
it is under this backdrop that silence decided in q2 2015 to increase investment in galnac - sirna conjugates for liver delivery . in april 2016 the company announced encouraging results from using an in - house structure , with potency observed believed to be competitive relative to peers . as a result , projects better suited to galnac will be transitioned to the technology , with liver therapeutics being a major focus for investment in the future . silence believes that its lipid nanoparticle delivery systems ( above ) are better suited to handling larger cargos , such mrna and for gene editing applications , with galnac best suited to rnai .
our technology is a highly specific and modular platform that enables us to inhibit or ‘silence’ the expression of disease - causing genes , allowing cells to revert to their healthy state .
the claims allowed on lipid complexes , the proprietary lipid which is a key element of silence ' s drug delivery technology atufect , cover any composition irrespective of the class of compound to be delivered and irrespective of the disease to be treated . the patent will both extend and widen silence ' s intellectual property ip related to the field of drug delivery .
david was appointed chief financial officer and company secretary of silence in july 2016 . david holds a b . a . in english & philosophy from birmingham university , and is a qualified chartered accountant . prior to joining silence , david’s relevant biotech experience includes several senior finance roles within both uk and us publicly owned life science companies , most recently as senior eumea finance director for biomarin pharmaceuticals inc . from 2010 to 2016 . prior to that he was cfo at plethora solutions plc ( 2008 - 2009 ) , and group financial controller at ark therapeutics from 2001 to 2008 , during which time ark undertook an ipo on the london stock exchange .
mortazavi told the financial news website proactive investors that silence intends to continue developing drugs on its own , rather than just buy other companies and have them perform the r & d work .
silence therapeutics plc is a united kingdom - based ribonucleic acid ( rna ) technology company . the company is primarily involved in the research and development of pharmaceutical products . the company ' s technology harnesses the body ' s natural mechanisms to create therapeutic effects within its own cells . the company has a has a genetic toolkit with its own therapeutic payloads to modulate gene expression up as well as down in preclinical in vivo models , and delivery systems for various organs and cell types .
silence therapeutics plc ( formerly sr pharma plc , formerly stanford rook holdings plc ) develops a new generation of medicines by harnessing the body ' s natural mechanism of rna interference , or rnai , within its cells . its proprietary technology can selectively inhibit any gene in the genome , specifically silencing the production of disease - causing proteins . using its enabling delivery systems , it has achieved an additional level of specificity by delivering our therapeutic rna molecules exclusively to target cells . silence ' s proprietary rna chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells , providing a powerful modular technology well suited to tackle life - threatening diseases .
we welcome the decision of the uspto on drug delivery as an appreciation of silence ' s contribution . drug delivery is key for the therapeutic use of functional nucleic acid molecules such as sirna and mirna . with this patent , silence is becoming an even more attractive partner for companies interested in the delivery of a variety of classes of compounds with sirna and mirna being only two of them .
another delivery method being worked on by silence is “galnac” , a highly efficient , simple and specific delivery approach whereby a sugar molecule ( n - acetylgalactosamine , galnac ) is conjugated to the sirna molecule .
there are currently 70 , 021 , 624 shares in issue and the average daily traded volume is 5 , 564 shares . the market capitalisation of silence ther . is £104 , 332 , 219 . 76 .
the claims allowed on interfering rna molecules cover any double - stranded ribonucleic acid molecule where o - alkyl modified nucleotides are alternating with unmodified or differently modified nucleotides on both strands having a length of 17 to fewer than 30 ribonucleotides . this kind of modified double - stranded ribonucleic acid molecules form a key component of silence ' s rnai therapeutics . the patent will extend silence ' s intellectual property related to double - stranded ribonucleic acid molecules to include molecules of 17 to fewer than 30 base pairs in length for use in methods for the treatment of disease . importantly , the patent will protect any such double - stranded ribonucleic acid molecule across all therapy areas and cover double - stranded ribonucleic acid molecules irrespective of the specific nucleotide sequence used .
silence’s investment comes following its may 2015 fundraise , subsequent to which the company has been looking at a number of rnai assets within both listed and unlisted companies . proving further value creating opportunities , silence has stated that the investment in arrowhead is a precursor to potential future deals which could include product licensing , r & d collaboration , technology sharing or a potential corporate transaction ( although no talks over a transaction are in progress at present ) .
if a gene sends out too many mrnas ( or “over - expresses” itself ) a cell can produce too much of a certain protein , potentially leading to diseases such as cancer , diabetes and many others . rnai is the method used to reduce the number of mrnas which get translated to these disease causing proteins . it minimises the over - expression of genes – effectively turning off , or silencing ( hence the name ) the disease causing genes . it is this area upon which silence therapeutics is focused , having developed proprietary rnai molecules and delivery systems .
president and chief executive officer of plaquetec limited . non - executive director of ardelyx inc , iox therapeutics limited , oncimmune holdings plc , thrombolytic science international , phesi llc and avrobio inc . chair of vium inc , cocoon biotech inc and cell medica limited . committee member of the u . s . food & drug administration science board .
silence is the only listed rnai player in europe and a pioneer in this technology . through the efforts of our skilled scientists over the years we have established a robust platform that allows us to effectively trigger rnai in specific cell types .
silence said it acquired about 8 . 4 percent of the outstanding shares of common stock in arrowhead ( nasdaq : arwr ) , which is based in pasadena , ca , but houses its research and development team in madison , wi .
the trial met its primary endpoint , with no safety issues being identified for the combination of atu027 with chemotherapy drug gemcitabine . silence now intends to progress atu027 through a suitable partnership rather than using its cash resources to fully develop it itself .
sr pharma , which rose out of stanford rook ltd . and has since changed its name to silence therapeutics , is a biotechnology company which was developing treatments derived from heat - killed mycobacterium vaccae ( nctc11659 ) and called srl172 or srp299 ( depending on the manufacturing process used ) in the 1990s . one of the founders of stanford rook , professor john stanford , helped dr charles akle to set up immodulon in 2007 . immodulon bought the rights to m . vaccae and is now continuing development under the name imm‑201 using an improved manufacturing process and target indications which are more relevant to its known mode of action .
silence therapeutics shares currently trade at 89p , capitalising the company at £62 . 1 million . with the last reported cash figure ( £47 . 59 million at as 30 th june 2016 ) being 8 months old , we estimate , based upon r & d and admin expenses being maintained at levels seen over the prior 18 months , and accounting for the transaction in arrowhead shares , that cash plus available for sale investments ( arwr ) currently stand at c . £43 million . thus , the markets are valuing the business , which incorporates the valuable intellectual property portfolio and programme of clinical trials , at just £19 . 1 million .
our technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells . this technology can selectively silence or replace any gene in the genome , modulating gene expression up as well as down in a variety of organs and cell types , in vivo .
arrowhead , for its part , emphasized that silence’s investment is the only official business the two firms have done together up to this point . “there have been no discussions about any potential transaction between the two companies , ” arrowhead said in a separate news release .
at silence we are developing novel rnai based therapies with the potential to transform patients’ lives . we use our proprietary technology platform to advance the next generation of genetic medicines , designed to intervene at the root of the problem by targeting the expression of disease - causing genes .
the company’s patented rnai chemistry is known as aturnai® , a proprietary technology with which individual sirna molecules are stabilised against degradation within the body . it is made up of highly potent , chemically stabilised sirna molecules which offer greater stability and better tolerability over conventional sirna molecules . aturnai® is one of the most thoroughly tested rnai therapeutics in humans and has an excellent safety record , with over 400 people dosed so far .
silence’s current enterprise value should prove to be no problem for larger pharma industry players to pay . in particular , we note that alnylam , largely considered to be the market leader in galnac technology , had cash & marketable securities of $ 1 . 04 billion as at 30 th september 2016 .
the delivery systems are subject to various patent families extending the scope of protection to the specific composition and use of the delivery systems . with the technologies able to deliver rna molecules to a wide variety of disease tissue silence has the opportunity to partner with other companies working in , or looking to enter , the rna field .
in interim results released last september the company revealed that in the previous six months it had obtained advice from three separate law firms indicating that multiple sirna based drugs currently in clinical development potentially fall within its issued claims . in reaction , silence has invited the relevant companies , which have remained un - named , to enter licensing negotiations .
settlement was recently reached over arbitration proceedings with quark over a milestone payment under the licensing deal in relation to qpi - 1002 . following the agreement silence will now receive a $ 1 million cash payment and is also eligible to receive either c . 2 % royalties plus milestones or 15 % of the clinical , regulatory and commercial milestone payments and royalties received by quark from partner novartis .
it has at least put the brakes on the share price . who knows - if there ' s any truth to the suggestions that alnylam might look to settle the patent dispute by taking over silence then now might be a good time to strike . certainly it seemed to me from the alnylam call that alnylam see the fitusiran death as tragic but by no means an end to their hopes for the drug .
arrowhead said on monday that it plans to continue development of several drug candidates , none of which are currently in clinical trials . the company is developing some candidates independently , but on others it is collaborating with partners , including amgen ( nasdaq : amgn ) , a large pharmaceuticals company based in thousand oaks , ca . in its release announcing the investment from silence , arrowhead said it will “continue to seek partnerships and collaborations that maximize the value of its assets . ”
delivering sirna into the body has long been a challenge for the rnai industry . in order to exert its effects , sirna must be safely and efficiently delivered into the target cells within the body , penetrate the cell membrane and survive for a sufficient amount of time once inside the cell . to address this challenge silence has developed a number of core proprietary liposomal delivery systems atuplex® , dacc , hepaplex and macplex , focused on delivering its specially modified aturnai® molecules to a variety of organs .
silence is the only listed rnai player in europe and a pioneer in this technology . through the efforts of our skilled scientists over the years we have established a robust platform that allows us to effectively trigger rnai in specific cell types . our inventions are protected by a broad intellectual property estate , which is a fundamental asset . together with our progress , the fact that the field is generally maturing means that rnai drugs are close to becoming a powerful genetic medicine modality at the disposal of doctors and patients .
dr . jenkins is a biopharma thought leader with 25 years of industry experience . until november 2017 , she was president and chief executive officer at leading gene therapy company , dimension therapeutics . prior to joining dimension in september 2014 , annalisa served as head of global research and development at merck serono pharmaceuticals from 2013 to 2014 , where she also served as executive vice president global development and medical from 2011 to 2013 . prior to this , dr . jenkins held several leadership roles at bristol myers - squibb from 1997 to 2011 , most recently serving as senior vice president and head of global medical affairs . earlier in her career , dr . jenkins was a medical officer in the british royal navy during the gulf conflict , achieving the rank of surgeon lieutenant commander .
in january 2009 quark announced the initiation of phase i / ii clinical trials for its drug candidate qpi - 1002 for the prevention of delayed graft function ( dgf ) in deceased donor adult kidney transplant patients . trials of the drug ( which are in partnership with novartis and incorporate silence’s aturnai® technology ) have progressed well , with phase iii trials in dgf , along with a phase ii study in acute kidney injury ( aki ) , currently ongoing . both trials are expected to have readouts in mid - 2018 , which provides a potential share price catalyst .
january this year saw silence use its cash resources to invest , on - market , in nasdaq listed arrowhead pharmaceuticals ( nasdaq : arwr ) . as at 13 th january a 9 . 21 % equity stake in arrowhead had been acquired , which will be held as an investment asset on the balance sheet . a total of $ 11 . 3 million was spent on the acquisition , equating to an average buying price of c . 165 cents per share . the shares currently trade at 212 cents , giving a gain on investment to date of c . 28 % .
dr . andrew j . richards is non - executive chairman at ixico plc , chairman at abcodia ltd . , chairman at cambridge temperature concepts ltd . , chairman at congenica ltd . , chairman at novacta biosystems ltd . , council member at biotechnology & biological sciences research council and a member at biological sciences research council . he is on the board of directors at silence therapeutics plc , cancer research technology ltd . , cambridge university hospitals nhs foundation trust , croggan ltd . , ieso digital health ltd . , arecor ltd . , babraham bioscience technologies ltd . and british science association . dr . richards was previously employed as independent non - executive director by summit corp . plc , independent non - executive director by vectura group plc , non - executive director by biowisdom ltd . , director - business development by chiroscience group plc , executive director by chiroscience ltd . , non - executive director by aitua ltd . , chairman by altacor ltd . , a principal by astrazeneca plc , a member by cancer research uk , executive director by celltech plc , chairman by ixico ltd . , non - executive director by pharmakodex ltd . , and non - executive director by theradeas ltd . he also served on the board at amedis pharmaceuticals ltd . , cambridge biotechnology ltd . , daniolabs ltd . , electra - net group ltd . and the bioindustry association . he received his doctorate degree from the university of cambridge .
– negative investor sentiment towards the rnai sector presents buying opportunity . as we have discussed above with arrowhead , companies involved in the rnai sector have seen a number of setbacks in recent months . share prices amongst rnai companies have plummeted , including a c . 70 % fall over the past 18 months for alnylam pharmaceuticals ( alny : nasdaq ) after the company announced the halting of several clinical trials . shares in dicerna pharmaceuticals ( drna : nasdaq ) , which is being sued by alnylam for “trade secret misappropriation” , are down by c . 90 % in just under two years and are currently trading at below cash . there is no negative read - across from any of these events to silence’s technology or activities in our view . thus , we believe that the present environment provides investors an opportunity to enter this highly prospective sector at a time when valuations are at the bottom of the cycle .
our management team is highly experienced in a variety of relevant sectors , from molecular biology and genetics to finance and investment banking .
our board of directors is formed by six accomplished members , two executive and four non - executive directors .
as the rna field evolves at an ever - faster rate , our tab helps us to assess its competitive position in technology and offers guidance in developing it in the most effective way .
we are committed to creating collaborations that maximise value for each of the partners .
effective sirna delivery to the right cells is a challenge given the complexity of the human body . discover how we address this .
find out more about our investment case , share price , corporate governance and related information . download our latest reports and announcements .
a summary of relevant information for our shareholders , investor faqs and key adviser details .
our upgraded , patient - friendly delivery technology is suitable for applications in a variety of disease settings . our liver centric pipeline is currently build around three main areas of high unmet need : haematology , metabolic and rare diseases .
we out - licensed our sirna stabilisation chemistry technology ( aturnai tm ) to quark pharmaceuticals , who have progressed drug candidates that use this technology to late clinical trials .
we have developed proprietary stabilising chemistries to improve the robustness of sirna sequences , together with advanced delivery systems that enable us to specifically target relevant cell types . this results in potent and highly specific drug candidates .
our inventions are protected by a broad intellectual property estate , which is a fundamental asset . together with our progress , the fact that the field is generally maturing means that rnai drugs are close to becoming a powerful genetic medicine modality at the disposal of doctors and patients .
we have out - licensed our sirna stabilisation chemistry technology ( aturnai tm ) to quark pharmaceuticals , who have progressed drug candidates that use this technology in late - stage clinical trials .
research in rnai has been progressing over the past 20 years , achieving nobel prize recognition in 2006 , and can now be seen to be transitioning from the experimental realm into the clinical . it is not often as an employee that you get a chance to be part of a nascent field like this that will make an impact on medicine .
we offer a vibrant culture and environment where innovation and creativity is encouraged . small , dynamic , with slick decision making and unencumbered by bureaucracy , we recognise contributions wherever they may be made within our team . our focus is on results , and opportunities for early career progression are here for team members who exceed their goals .
we should also mention we hope to have a lot of fun on the way , fully embracing the multi cultural mix of the talented professionals we employ .
our teams are located in west london , which is our corporate headquarters , and berlin where the majority of our research & development staff are based .
please review our current vacancies which are listed below . we are also interested to hear from candidates on a speculative basis either via the enquiries box or via e - mail to
our management team is highly experienced in a variety of relevant sectors , from molecular biology and genetics to finance and investment banking . this combination of skill sets enables the team to effectively execute our business plan .
our business model is designed to bring solutions to patients while generating shareholder value , by translating our proprietary technology into commercial drug products in a rapid and cost - effective way .
our corporate governance framework is based on using the leadership provided by our board to drive the effective execution of our strategy , ensuring that risk is appropriately mitigated and managed .
we have three board committees ( remuneration , audit and risk , and nominations ) , focused on providing the required oversight to maintaining the highest corporate governance standards . through these committees and regular interactions with the executive team , our board applies internal financial controls and approves the company’s policy and strategy .
the london stock exchange uses cookies to improve its website . the cookies for analytical purposes have already been set . for more details and how to manage cookies , please see our privacy and cookies policy .
as at 09 - jul - 2018 21 : 00 : 10 - all data delayed by at least 15 minutes .
* for instruments denominated in gbx , the trade value is shown in gbp when the traded currency is gbx or gbp . when the traded price is any other currency then the trade value is displayed in that currency .
* the company market capitalization reflects the london listed element of ordinary and preference shares only and is approximate . data provided by ftse russell .
the exchange accepts no responsibility for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it .
by allowing this link the exchange does not intend in any country , directly or indirectly , to solicit business or offer any securities to any person .
the exchange accepts no responsibility for the content of the reports you are now accessing or for any reliance placed by you or any person on the information contained therein .
72 hammersmith road london w14 8th p : + 4420 . 34576900 f : + 447 . 957318494
reuters , the news and media division of thomson reuters , is the world’s largest international multimedia news provider reaching more than one billion people every day . reuters provides trusted business , financial , national , and international news to professionals via thomson reuters desktops , the world ' s media organizations , and directly to consumers at urltoken and via reuters tv . learn more about thomson reuters products :
all quotes delayed a minimum of 15 minutes . see here for a complete list of exchanges and delays .
immuno - oncology company apeiron biologics ag ( vienna , austria ) hired peter llewellyn - davies as cfo and cbo . he was cfo and cbo at medigene ag ( xetra : mdg1 ) . infectious disease company tetraphase pharmaceuticals inc . ( nasdaq : ttph ) named kamalam unninayar cfo . she . . .
neurological diseases play flex pharma inc . ( nasdaq : flks ) said christoph westphal will step down as ceo , effective july 3 . he will remain chairman . president of r & d william mcvicar will be interim ceo . cancer company viratherapeutics gmbh ( innsbruck , . . .
gruenenthal group ( aachen , germany ) named gabriel baertschi ceo , effective oct . 1 . he will replace eric - paul paques , who will retire . baertschi is country president for japan at astrazeneca plc ( lse : azn ; nyse : azn ) . cns play forum pharmaceuticals inc . . . .
final data from the phase iia portion of the open - label , german phase ib / iia atu027 - i - 02 trial in 23 patients with locally advanced or metastatic pancreatic adenocarcinoma showed that twice - weekly atu027 for 4 weeks plus once - weekly gemcitabine . . .
having addressed one of the two big problems of rnai delivery - getting therapeutic levels of the molecules inside cells - arrowhead research corp . now believes it has solved the second , with a modification to . . .
a post hoc analysis of the subgroup of 19 patients with metastatic pancreatic adenocarcinoma in the phase iia portion of the open - label , german phase ib / iia atu027 - i - 02 trial showed that twice - weekly atu027 for 4 weeks plus . . .
news corp is a network of leading companies in the worlds of diversified media , news , education , and information services .
real - time u . s . stock quotes reflect trades reported through nasdaq only .
international stock quotes are delayed as per exchange requirements . indexes may be real - time or delayed ; refer to time stamps on index quote pages for information on delay times .
quote data , except u . s . stocks , provided by six financial information .
data is provided
as is
for informational purposes only and is not intended for trading purposes . six financial information ( a ) does not make any express or implied warranties of any kind regarding the data , including , without limitation , any warranty of merchantability or fitness for a particular purpose or use ; and ( b ) shall not be liable for any errors , incompleteness , interruption or delay , action taken in reliance on any data , or for any damages resulting therefrom . data may be intentionally delayed pursuant to supplier requirements .
© thomson reuters . all rights reserved . any copying , republication or redistribution of lipper content , including by caching , framing or similar means , is expressly prohibited without the prior written consent of lipper . lipper shall not be liable for any errors or delays in the content , or for any actions taken in reliance thereon .
for inquiries related to this message please contact support . for sales inquiries , please visit urltoken
if you believe this to be in error , please confirm below that you are not a robot by clicking
i ' m not a robot
below .
please make sure your browser supports javascript and cookies and that you are not blocking them from loading . for more information you can review the terms of service and cookie policy .
dr . annalisa mary jenkins frcpc , mbbs , frcp , mrcp , f . r . c . p .
and compensation values are for the last fiscal year ending on that date . pay is salary , bonuses , etc . exercised is the value of options exercised during the fiscal year . currency in usd .
the pillar scores are audit : n / a ; board : n / a ; shareholder rights : n / a ; compensation : n / a .
scores indicate decile rank relative to index or region . a decile score of 1 indicates lower governance risk , while a 10 indicates higher governance risk .
arrowhead research is focused on developing , commercializing , and licensing a range of nanotechnology products and applications .
sign up for a free crunchbase account to follow and track organizations you care about .
terms of service | privacy policy | © 2018 crunchbase inc . all rights reserved .
descriptive keyword for an organization ( e . g . saas , android , cloud computing , medical device )
this field describes an organization ' s most recent funding status ( e . g . early stage venture , late stage venture , m & a )
last funding round type ( e . g . series a , seed , private equity )
transaction name : auto - generated name of transaction ( e . g . angel - uber )
transaction name : auto - generated name of transaction ( e . g . whatsapp acquired by facebook )
glassdoor will not work properly unless browser cookie support is enabled . learn how to enable cookies .
explore the many benefits of having a premium branded profile on glassdoor , like increased influence and advanced analytics .
changes won ' t be saved until you sign up for an enhanced profile subscription .
the cso at the time was a very good person and scientist that was always nice and make you feel comfortable . easy discussion with internal referral from university . easy question about lipids , sirna and oligonucleotide in general . german and english question . opportunity to come back after postdoc in the usa .
copyright © 2008–2018 , glassdoor , inc .
glassdoor
and logo are proprietary trademarks of glassdoor , inc .
the company highlighted that chemical modification technology is vital to prevent the degradation of therapeutic short interfering rna ( sirna ) molecules and to enable potent rna interference ( rnai ) , and as such it can have a substantial impact on the performance of rnai drugs .
the company is a publisher . you understand and agree that no content published on the site constitutes a recommendation that any particular security , portfolio of securities , transaction , or investment strategy is suitable or advisable for any specific person . you further understand that none of the information providers or their affiliates will advise you personally concerning the nature , potential , advisability , value or suitability of any particular security , portfolio of securities , transaction , investment strategy , or other matter .
you understand that the site may contain opinions from time to time with regard to securities mentioned in other products , including company related products , and that those opinions may be different from those obtained by using another product related to the company . you understand and agree that contributors may write about securities in which they or their firms have a position , and that they may trade such securities for their own account . in cases where the position is held at the time of publication and such position is known to the company , appropriate disclosure is made . however , you understand and agree that at the time of any transaction that you make , one or more contributors may have a position in the securities written about . you understand that price and other data is supplied by sources believed to be reliable , that the calculations herein are made using such data , and that neither such data nor such calculations are guaranteed by these sources , the company , the information providers or any other person or entity , and may not be complete or accurate .
from time to time , reference may be made in our marketing materials to prior articles and opinions we have published . these references may be selective , may reference only a portion of an article or recommendation , and are likely not to be current . as markets change continuously , previously published information and data may not be current and should not be relied upon .
proactive investors limited , trading as “proactiveinvestors united kingdom” , is authorised and regulated by the financial conduct authority . registered in england with company registration number 05639690 . group vat registration number 872070825 fca registration number 559082 . you can contact us here . market indices , commodities and regulatory news headlines copyright © morningstar . data delayed 15 minutes unless otherwise indicated . terms of use
described as being one of the most important recent discoveries in life sciences , rnai can selectively suppress disease causing genes . it has the potential to create a new class of therapeutic products for a broad range of diseases , many of which have an unmet need .
first discovered in the late 1990s , rna interference ( rnai ) is a highly prospective and rapidly advancing area of biotechnology concerned with gene suppression , or “gene silencing” – a process which enables the regulation of gene expression ( the process whereby information from a gene is used to produce proteins and rna ) . rnai is a naturally occurring process that occurs in organisms ranging from plants to mammals and can be utilised to selectively suppress the genes which cause certain diseases . this is done by preventing the over - expression of the gene and thus reducing the production of disease causing protein .
described as being one of the most important recent discoveries in life sciences , and one of the most exiting areas of drug discovery today , rnai technology has made significant leaps forward over the past decade , with the 2006 nobel prize in physiology or medicine being awarded to andrew fire and craig mello for , “their discovery of rna interference – gene silencing by double - stranded rna” .
having attracted the attention and investment of large pharma and other smaller specialist research companies , a number of rnai driven drugs are now moving to later stage clinical trials . however , the market remains at an early stage of development , with no rnai based drugs having been approved to date .
the nucleus of each living cell contains dna ( deoxyribonucleic acid ) , where specific genes and their genetic codes are stored . dna is the blueprint for the manufacture of proteins , the building blocks of life which enable the body to function . to pass on its instructions , dna itself does not leave the cell nucleus but instead creates a temporary copy of its genetic information . this copy is known as messenger rna ( mrna ) , an rna molecule which can leave the nucleus and transmits instructions to a cell’s ribosomes , the cell component responsible for synthesizing protein .
when rnai molecules are administered to patients they are absorbed into target cells . also known as short interfering rna ( sirna ) , these molecules in effect carry the “anti - code” to that of the mrnas which are being over - produced . once the sirnas bind to the mrnas the genetic code has been “interfered” with and can no longer be translated for protein production . as a result , protein production reduces , improving the diseased state .